DOCSLIB.ORG

Latest List of Pharmacy Only Medicinal Products Not Subject to Medical Prescription This List Was Last Updated on Thursday, September 23, 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Latest List of Pharmacy Only Medicinal Products Not Subject to Medical Prescription This List Was Last Updated on Thursday, September 23, 2021 Latest list of pharmacy only medicinal products not subject to medical prescription This list was last updated on Thursday, September 23, 2021 Please Note The contents of the table are believed to be correct at the time of compilation. The HPRA makes no representations or warranties about and disclaim all liability for the content, accuracy, completeness or suitability of the information contained in the table for any purpose whatsoever and the information is made available to the public for information purposes only. For any conditions associated with this general sale classification please refer to the detailed product information on the Human Medicines Product listing on the HPRA website. Please note that at time of print some products listed below may not be currently marketed. Part 1. Latest list of pharmacy only medicinal products not subject to medical prescription Trade Name Licence Holder Licence Strength Dosage Form Active Number Ingredients A.Vogel Uva-ursi & A. Vogel Ireland TR2309/021/001 . Oral drops, solution Echinacea Cystitis Ltd, oral drops Abidec Multivitamin Chefaro Ireland PA1186/001/001 25 millilitre(s) Oral drops, solution -Vitamin a palmitate Oral Drops Solution DAC -Ergocalciferolci -Thiamine hydrochloride -Riboflavin sodium phosphate -Pyridoxine hydrochloride -Nicotinamide -Ascorbic acid Acic 5% Cream Rowex Ltd PA0711/017/001 5 percent Cream -ACICLOVIR Acidex Oral Pinewood PA0281/075/001 500mg+267mg+16 Oral suspension -Sodium alginate SuspensionSodium Laboratories Ltd, 0 milligram/ 10 -Sodium Alginate millilitre bicarbonate 500mg,Sodium -Calcium carbonate Bicarbonate 267mg,Calcium Carbonate 160mg/10ml Acnecide 5% w/w Galderma PA22743/001/001 5 percent Gel -Benzoyl peroxide Gel International S.A.S. weight/weight Acnecide Wash 5 Galderma PA22743/001/002 5 percent Gel -Benzoyl peroxide % w/w Gel International S.A.S. weight/weight ACTIFED Johnson & Johnson PA0330/049/001 30 mg/1.25 mg/5ml Syrup - 30mg/1.25mg per (Ireland) Limited PSEUDOEPHEDR 5ml Syrup INE HYDROCHLORIDE -TRIPROLIDINE HYDROCHLORIDE Latest list of pharmacy only medicinal products not subject to medical prescription Page 1 of 35 Trade Name Licence Holder Licence Strength Dosage Form Active Number Ingredients Actifed Johnson & Johnson PA0330/049/002 60 mg/2.5 Tablet -TRIPROLIDINE 60mg/2.5mg (Ireland) Limited milligram(s) HYDROCHLORIDE Tablets - PSEUDOEPHEDR INE HYDROCHLORIDE Actiprofen 200 mg GlaxoSmithKline PA0678/061/002 200 milligram(s) Film-coated tablet -Ibuprofen tablets Consumer Healthcare (Ireland) Limited Advil Cold & Flu GlaxoSmithKline PA0678/147/001 200/30 milligram(s) Coated tablet -Ibuprofen Coated Consumer - TabletsIbuprofen Healthcare (Ireland) PSEUDOEPHEDR 200mgPseudoeph Limited INE edrine HYDROCHLORIDE Hydrochloride 30mg Advil Cold & Flu GlaxoSmithKline PA0678/147/002 200 mg/30 Capsule, soft -Ibuprofen Relief Soft Consumer milligram(s) - Capsules Ibuprofen Healthcare (Ireland) PSEUDOEPHEDR 200mg Limited INE Pseudoephedrine HYDROCHLORIDE Hydrochloride 30mg Agiolax 52%w/w, Madaus GmbH PA1288/002/001 52%w/w+2.2%w/w Granules -Senna - tinnevelly / 2.2%w/w and 6.74- + 6.74%w/w+13.2 indian 13.2%w/w percent -Ispaghula husks Granules weight/weight -Ispaghula Alli GlaxoSmithKline EU/1/07/401/12-15 27 milligram(s) Chewable tablet -Orlistat Dungarvan Limited Alli GlaxoSmithKline EU/1/07/401/1-6 60 milligram(s) Capsule, hard -Orlistat Dungarvan Limited Alli GlaxoSmithKline EU/1/07/401/7-11 60 milligram(s) Chewable tablet -Orlistat Dungarvan Limited Ametop 40 mg/g Alliance Pharma PA2325/002/001 40 Gel -Tetracaine base Gel (Ireland) Limited milligram(s)/gram Anbesol Alliance Pharma PA2325/003/001 . Oromucosal -Cetylpyridinium Anaesthetic (Ireland) Limited solution chloride Antiseptic -Lidocaine Oromucosal hydrochloride Solution -Chlorocresol Anhydrol Forte 20 IMED Healthcare DPR1463/048/001 20 percent Not Currently -Aluminium chloride Ltd. Available hexahydrate Anhydrol Forte 20% Dermal PA23128/004/001 20 percent Cutaneous solution -Aluminium chloride w/v Cutaneous Laboratories weight/volume hexahydrate Solution (Ireland) Limited Anthisan Cream Sanofi-Aventis PA0540/092/001 2 percent Cream -Mepyramine 2% w/w Ireland Limited T/A weight/weight maleate SANOFI Anti-Hist Allergy Clonmel Healthcare PA0126/267/001 10 milligram(s) Film-coated tablet -Cetirizine 10mg Film-coated Ltd dihydrochloride tablets Anti-Hist Allergy Clonmel Healthcare PA0126/267/002 1 Oral solution -Cetrizine 1mg/ml Oral Ltd milligram(s)/millilitr dihydrochloride Solution Latest list of pharmacy only medicinal products not subject to medical prescription Page 2 of 35 Trade Name Licence Holder Licence Strength Dosage Form Active Number Ingredients Anusol HC SOFIBEL PA22647/002/001 0.25/1.25/2.25/0.8 Ointment -Zinc oxide Ointment 75/1.875/10.75 -Balsam peru gram/100gram -Bismuth oxide -Bismuth subgallate -Benzyl benzoate - HYDROCORTISO NE ACETATE Anusol HC SOFIBEL PA22647/002/002 2.8 mg percent Suppository -Bismuth subgallate Suppositories weight/weight -Zinc oxide -Bismuth oxide -Balsam peru -Benzyl benzoate - HYDROCORTISO NE ACETATE Anusol SOFIBEL PA22647/001/003 1 Suppository -Bismuth oxide Suppositories -Zinc oxide -Balsam peru -Bismuth subgallate Aquasept Skin Ayrton Saunders PA22906/003/001 20 Cutaneous solution -Triclosan Cleanser 20mg/ml (Ireland) Limited milligram(s)/millilitr Cutaneous Solution Arret 2 mg Hard PCO Manufacturing PPA0465/155/001 2 milligram(s) Capsule, hard -LOPERAMIDE Capsules Ltd. HYDROCHLORIDE Arret 2mg Hard Johnson & Johnson PA0330/042/001 2 milligram(s) Capsule, hard -LOPERAMIDE Capsules (Ireland) Limited HYDROCHLORIDE Artelac 3.2 mg/ml Bausch Health PA22698/010/001 3.2 Eye drops, solution -Hypromellose Eye Drops, Solutio Ireland Limited milligram(s)/millilitr Artelac Bausch Health PA22698/010/002 3.2 Eye drops, solution -Hypromellose Preservative Free Ireland Limited milligram(s)/millilitr Single Dose Unit Artelac Lexon (UK) Ltd PPA1097/060/001 3.2 Eye drops, solution -Hypromellose Preservative Free milligram(s)/millilitr Single Dose Unit Artelac IMED Healthcare PPA1463/099/001 3.2 Eye drops, solution -Hypromellose Preservative Free Ltd. milligram(s)/millilitr Single Dose Unit 3.2 mg/ml Eye Drops Solution Artelac PCO Manufacturing PPA0465/454/001 3.2 milligram(s) Eye drops, solution -Hypromellose Preservative Free Ltd. Single Dose Unit 3.2 mg/ml eye drops, solution Arthrimel 1500mg Phoenix Labs PA1113/011/003 1500 milligram(s) Film-coated tablet -Glucosamine Film Coated sulfate Tablets Arthrimel 500 mg Phoenix Labs PA1113/011/001 500 milligram(s) Film-coated tablet -Glucosamine Film-Coated sulfate Tablets Arthrimel 750mg Phoenix Labs PA1113/011/002 750 milligram(s) Film-coated tablet -Glucosamine Film Coated sulfate Tablets Audax Ear Drops LanesHealth PA22702/003/001 20 %w/v +12.6 Ear drops, solution -Choline salicylate Solution Choline (Ireland) Limited percent -Glycerol Salicylate 20%w/v weight/volume Glycerol 12.6%w/v Latest list of pharmacy only medicinal products not subject to medical prescription Page 3 of 35 Trade Name Licence Holder Licence Strength Dosage Form Active Number Ingredients Beconase Hayfever Chefaro Ireland PA1186/008/001 50 Mcg/Dose Nasal spray, -Beclometasone nasal spray 50 DAC suspension dipropionate micrograms per spray Belladonna 0.25% Cuxson Gerrard & PA0229/004/001 0.25 percent Medicated plaster -Belladonna w/w Medicated Company Ltd weight/weight alkaloids Plaster Benylin Children’s Johnson & Johnson PA0330/026/001 50 mg/5ml Syrup -Guaifenesin Chesty Cough (Ireland) Limited 50mg/5ml Syrup Benylin Children’s Johnson & Johnson PA0330/022/001 7mg/5ml + 0.55 Syrup -Levomenthol Dry Coughs (Ireland) Limited mg/5ml -Diphenhydramine SyrupDiphenhydra hydrochloride mine Hydrochloride 7mg/5mlLevoment hol 0.55mg/5ml Benylin Cough Johnson & Johnson PA0330/019/001 14 mg/5 ml + 1.1 Syrup -Diphenhydramine Medicine (Ireland) Limited mg/5ml hydrochloride SyrupDiphenhydra -Levomenthol mine hydrochloride 14mg/5mlLevomen thol 1.1mg/5ml BENYLIN Day & Johnson & Johnson PA0330/020/001 500/60 and 500/25 Film-coated tablet -Paracetamol Night Tablets, (Ireland) Limited milligram(s) -Pseudoephedrine 500mg/60mg hydrochloride tablets and -Paracetamol 500/25mg film- -Diphenhydramine coated tablets hydrochloride Benylin Dry Coughs Johnson & Johnson PA0330/018/001 14 mg/5ml + 6.5 Syrup -Diphenhydramine Syrup (Ireland) Limited mg/5ml + 2 mg/5ml hydrochloride Diphenhydramine -Dextromethorphan hydrochloride hydrobromide 14mg/5ml -Levomenthol Dextromethorphan hydrobromide 6.5mg/5ml Levomenthol 2mg/5ml Benylin Dual Action Johnson & Johnson PA0330/015/002 30 mg/10 mg/1.25 Powder and solvent -TRIPROLIDINE Dry Syrup, (Ireland) Limited mg/5ml for solution for HYDROCHLORIDE Pseudoephedrine injection in pre-filled - 30mg, syringe PSEUDOEPHEDR Dextromethorphan INE 10mg, Triprolidine HYDROCHLORIDE 1.25mg -Dextromethorphan hydrobromide Benylin Four Flu Johnson & Johnson PA0330/028/001 500 mg/12.5 Film-coated tablet -Paracetamol Film-Coated (Ireland) Limited mg/22.5 - Tablets. milligram(s) PSEUDOEPHEDR Paracetamol INE 500mg HYDROCHLORIDE Diphenhydramine -Diphenhydramine hydrochloride hydrochloride 12.5mg Pseudoephedrine hydrochloride 22.5mg Benylin Mucus McNeil Healthcare PA0823/035/001 250 mg/5ml Syrup -Carbocisteine Relief 250mg/5ml (Ireland) Ltd Syrup Latest list of pharmacy only medicinal products not subject to medical prescription Page 4 of 35 Trade Name Licence Holder Licence Strength Dosage Form Active Number Ingredients Benylin Non- Johnson & Johnson PA0330/025/001 7.5 mg/5ml Syrup -Dextromethorphan Drowsy Dry (Ireland) Limited hydrobromide Coughs,
Load more

Recommended publications
  • The Management of Common Skin Conditions in General Practice
    Management of Common Skin Conditions In General Practice including the “red rash made easy” © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care University of Auckland, Tamaki Campus Reviewed by Hon A/Prof Amanda Oakley - 2019 http://www.dermnetnz.org Management of Common Skin Conditions In General Practice Contents Page Derm Map 3 Classic location: infants & children 4 Classic location: adults 5 Dermatology terminology 6 Common red rashes 7 Other common skin conditions 12 Common viral infections 14 Common bacterial infections 16 Common fungal infections 17 Arthropods 19 Eczema/dermatitis 20 Benign skin lesions 23 Skin cancers 26 Emergency dermatology 28 Clinical diagnosis of melanoma 31 Principles of diagnosis and treatment 32 Principles of treatment of eczema 33 Treatment sequence for psoriasis 34 Topical corticosteroids 35 Combination topical steroid + antimicrobial 36 Safety with topical corticosteroids 36 Emollients 37 Antipruritics 38 For further information, refer to: http://www.dermnetnz.org And http://www.derm-master.com 2 © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care, University of Auckland, Tamaki Campus. Management of Common Skin Conditions In General Practice DERM MAP Start Is the patient sick ? Yes Rash could be an infection or a drug eruption? No Insect Bites – Crop of grouped papules with a central blister or scab. Is the patient in pain or the rash Yes Infection: cellulitis / erysipelas, impetigo, boil is swelling, oozing or crusting? / folliculitis, herpes simplex / zoster. Urticaria – Smooth skin surface with weals that evolve in minutes to hours. No Is the rash in a classic location? Yes See our classic location chart .
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • No. 33981 2 No
    Pretoria, 4 February 2011 Februarle No. 33981 2 No. 33981 GOVERNMENT GAZETTE, 4 FEBRUARY 2011 IMPORTANT NOTICE The Government Printing Works will not be held responsible for faxed documents not received due to errors on the fax machine or faxes received which are unclear or incomplete. Please be advised that an "OK" slip, received from a fax machine, will not be accepted as proof that documents were received by the GPW for printing. If documents are faxed to the GPW it will be the sender's respon­ sibility to phone and confirm that the documents were received in good order. Furthermore the Government Printing Works will also not be held responsible for cancellations and amendments which have not been done on original documents received from clients. CONTENTS INHOUD Bladsy Koerant Page Gazette No. No. No. No. No. No. GENERAL NOTICE ALGEMENEKENNISGEWING Health, Department of Gesondheld, Departement van General Notice A/gemene Kennisgewing 58 Medicines and Related Substances Act 58 Wet op Beheer van Medisyne en (101/1965): Medicines Control Council: Verwante Stowwe (101/1965): Conditions of registration of a medicine Medisynebeheerraad: Voorwaardes vir in terms of the provisions of section die registrasie van 'n medisyne in terme 15 (7) ..................................................... .. 3 33981 van die bepalings van artikel 15 (7) ........ 4 33981 STAATSKOERANT, 4 FEBRUARIE 2011 No. 33981 3 GENERAL NOTICE ALGEMENE KENNISGEWING NOTICE 58 OF 2011 MEDICINES CONTROL COUNCIL CONDITIONS OF REGISTRATION OF A MEDICINE IN TERMS OF THE PROVISIONS OF SECTION 15(7) OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 1. The applicant shall ensure that the medicine is manufactured and controlled in terms of the current Good Manufacturing Practices as determined by Council 2.
    [Show full text]
  • Treatment of Diseases and Conditions Mediated By
    (19) TZZ_ ___T (11) EP 1 572 115 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 38/07 (2006.01) A61K 38/08 (2006.01) 21.01.2015 Bulletin 2015/04 A61K 38/17 (2006.01) A61K 38/38 (2006.01) (21) Application number: 03799853.1 (86) International application number: PCT/US2003/037901 (22) Date of filing: 25.11.2003 (87) International publication number: WO 2004/050023 (17.06.2004 Gazette 2004/25) (54) TREATMENT OF DISEASES AND CONDITIONS MEDIATED BY INCREASED PHOSPHORYLATION BEHANDLUNG VON ERKRANKUNGEN UND ZUSTÄNDEN,DIE DURCH ERHÖHTE PHOSPHORYLIERUNG VERMITTELT WERDEN TRAITEMENT DE MALADIES ET D’ETATS A MEDIATION DE PHOSPHORYLATION ACCRUE (84) Designated Contracting States: • JIANG B ET AL: "Phosphopeptides derived from AT BE BG CH CY CZ DE DK EE ES FI FR GB GR hen egg yolk phosvitin: effect of molecular size HU IE IT LI LU MC NL PT RO SE SI SK TR on the calcium-binding properties." BIOSCIENCE, BIOTECHNOLOGY, AND (30) Priority: 27.11.2002 US 429924 P BIOCHEMISTRY MAY 2001, vol. 65, no. 5, May 2001 (2001-05), pages 1187-1190, XP002549556 (43) Date of publication of application: ISSN: 0916-8451 14.09.2005 Bulletin 2005/37 • KATAYAMA SHIGERU ET AL: "Antioxidative stress activity of oligophosphopeptides derived (73) Proprietor: Ampio Pharmaceuticals, Inc. from hen egg yolk phosvitin in Caco-2 cells." Englewood, CO 80112 (US) JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 8 FEB 2006, vol. 54, no. 3, 8 February (72) Inventor: BAR-OR, David 2006 (2006-02-08), pages 773-778, XP002549557 Englewood, CO 80110 (US) ISSN: 0021-8561 • OKAMOTO ET AL: ’The interleukin-8 AP-1 and (74) Representative: Weber, Joachim kappa B-like sites are genetic end targets of Hoefer & Partner FK506-sensitive pathway accompanied by Patentanwälte calcium mobilization.’ JOURNAL OF Pilgersheimer Strasse 20 BIOLOGICAL CHEMISTRY vol.
    [Show full text]
  • Mcneil Consumer : Mdl No
    IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA IN RE: MCNEIL CONSUMER : MDL NO. 2190 HEALTHCARE, ET AL., MARKETING : AND SALES PRACTICES LITIGATION : : Applies to: : ALL ACTIONS : MEMORANDUM McLaughlin, J. July 13, 2012 This multidistrict litigation arises out of quality control problems at the defendants’ facility manufacturing over- the-counter healthcare products in Fort Washington, Pennsylvania, which led to a series of recalls of those products. The named plaintiffs assert claims for economic loss on behalf of a putative nationwide class against Johnson & Johnson (“J&J”), McNeil Consumer Healthcare (“McNeil”), and four of their executives. The plaintiffs allege that they overpaid for the defendants’ products as a result of the recalls and the defendants’ scheme to conceal or downplay the scope of the quality control problems. The defendants, who have offered a coupon or cash refund to consumers who purchased recalled drugs, have moved to dismiss the operative complaint, and assert that the named plaintiffs lack constitutional standing and have not met the applicable pleading standard. The Court will grant the defendants’ motion because the plaintiffs have not pled facts that show a cognizable injury in fact, which is required to confer Article III standing. I. Procedural Background This litigation resulted from the consolidation of ten individual actions filed around the country. Haviland v. McNeil Consumer Healthcare, No. 10-2195, was filed in this Court on May 12, 2010, asserting economic injuries arising out of the April 30, 2010 recall of over-the-counter children’s drugs by McNeil, a part of the J&J “Family of Companies.” Eight additional cases, also arising out of the April 2010 recall, were filed in district courts around the country.1 All cases asserted claims for economic injury only, with the exception of Rivera v.
    [Show full text]
  • Notice Under S66 of the Commerce Act 1986 Application by Johnson & Johnson to Acquire the Stock, Assets and Business Of
    PUBLIC COPY Notice under s66 of the Commerce Act 1986 Application by Johnson & Johnson to acquire the stock, assets and business of the Consumer Healthcare division of Pfizer Inc. COMMERCE ACT 1986: BUSINESS ACQUISITION SECTION 66: NOTICE SEEKING CLEARANCE 28 September 2006 The Registrar Business Acquisitions and Authorisations Commerce Commission PO Box 2351 Wellington Pursuant to s66(1) of the Commerce Act 1986 notice is hereby given seeking clearance of a proposed business acquisition. 518689_1.DOC 2 CONTENTS EXECUTIVE SUMMARY PART 1: TRANSACTION DETAILS 1 The business acquisition for which clearance is sought 2 The person giving this notice 3 Confidentiality 4 Participants 5 Interconnected and associated persons 6 Beneficial interests 7 Links between participants 8 Common directorships 9 Business activities of the participants 10 Reasons for the proposed acquisition PART II: IDENTIFICATION OF MARKETS AFFECTED 11 Horizontal aggregation 12 Differentiated product markets 13 Differentiated product markets 14 Vertical integration 15 Other business acquisitions PARTS III, IV AND V: CONSTRAINTS ON MARKET POWERS BY EXISTING AND POTENTIAL COMPETITION AND OTHER POTENTIAL CONSTRAINTS 16 Allergy medication 17 Products for the treatment of worms 18 Thrush treatment CERTIFICATE APPENDICES 1. Heartburn and indigestion remedies (MYLANTA and MOTILIUM) 2. Worm treatments (COMBANTRIN, VERMOX) 3. Cold, flu, nasal decongestant, cough relief and sort throat medications (CODRAL, SINUTAB, SUDAFED, BENADRYL, BRONDECON) 4. Allergy relief products (ACTIFED, SINUTAB, SUDAFED, VISINE, LIVOSTIN) 518689_1.DOC 3 5. Thrush treatments (DIFLUCAN ONE, DAKTARIN, DAKTAGOLD, NIZORAL, SPORANOX) 6. Shampoo (PREGAINE, ROGAINE, NEUTROGENA, JOHNSON’S BABY SHAMPOO) 7. Hand hygiene (PURELL and MICRO SHIELD) 8. Competitor worm treatment products 9. Multinational pharmaceutical businesses: GlaxoSmithKline, Douglas Pharmaceuticals, Alphapharm, Bayer Group 10.
    [Show full text]
  • Medication Code Key: PMCODE and Drug Name in 2007 NHHCS Cdc-Pdf
    Medication Code Key: PMCODE and Drug Name in 2007 NHHCS PMCODE Drug Name 00002 TAMIFLU 00003 DITROPAN XL II 00004 LIDODERM PATCH 00008 VIACTIV 00010 A AND D II 00013 MYCOPHENOLATE MOFETIL 00017 SIROLIMUS 00019 HAWTHORN 00027 SYNAGIS 00032 EXCEDRIN MIGRAINE 00036 MAALOX PLUS 00037 ACEON 00038 GLYSET 00039 SONATA 00042 PROTONIX 00044 PANLOR DC 00048 MOBIC 00052 SILDENAFIL CITRATE 00053 TAMSULOSIN HYDROCHLORIDE 00054 COMTAN 00058 MINERAL SUPPLEMENT 00061 BISMUTH 00071 CERTAVITE 00073 LUXIQ 00075 SAL-TROPINE 00076 TRILEPTAL 00078 AGGRENOX 00080 CARBIDOPA-LEVODOPA 00081 EXELON 00084 PREGABALIN 00085 ORAMORPH 00096 OSTEO-BIFLEX 00099 ALOCRIL 00100 A.S.A. 00101 ISOSORBIDE DINITRATE 00102 ISOSORBIDE MONONITRATE 00107 ROSIGLITAZONE MALEATE 00109 URSODIOL 00112 MEDERMA 00113 ANDROGEL 00114 DILTIA XT 00117 CRANBERRY 00123 NICOTINE 00125 AVELOX 00132 CAL-MAG 00133 CANDESARTAN Page 1 Medication Code Key: PMCODE and Drug Name in 2007 NHHCS PMCODE Drug Name 00148 PROLIXIN D 00149 D51/2 NS 00150 NICODERM CQ PATCH 00151 TUSSIN 00152 CEREZYME 00154 CHILDREN'S IBUPROFEN 00156 PROPOXACET-N 00159 KALETRA 00161 BISOPROLOL 00167 NOVOLIN N 00169 KETOROLAC TROMETHAMINE 00172 OPHTHALMIC OINTMENT 00173 ELA-MAX 00176 PREDNISOLONE ACETATE 00179 COLLOID SILVER 00184 KEPPRA 00187 OPHTHALMIC DROPS 00190 ABDEC 00191 HAPONAL 00192 SPECTRAVITE 00198 ENOXAPARIN SODIUM 00206 ACTONEL 00208 CELECOXIB 00209 GLUCOVANCE 00211 LEVALL 5.0 00213 PANTOPRAZOLE SODIUM 00217 TEMODAR 00218 CARBAMIDE PEROXIDE 00221 CHINESE HERBAL MEDS 00224 MILK AND MOLASSES ENEMA 00238 ZOLMITRIPTAN 00239
    [Show full text]
  • Solpadeine Max Tabs 03
    File title: 9034_SOMT01240812v1_Solpadeine Max tabs 20s-30s PIL v3F • If you take a painkiller for headaches for more than 3 days it can make Item No.: 11000000010649 PROSP SOLPADEINA MAX TABLETAS UK 1212 them worse. Last edit: 22nd November 2013 Do not take Solpadeine Max Tablets: Brand: Solpadeine Tablets Variant: MAX Tablets • If you have ever had an allergic reaction to paracetamol, codeine, other opioid painkillers or to any of the other ingredients (listed in Section 6) Component: Leaflet • If you are taking other medicines containing paracetamol or codeine • For pain relief in children and adolescents (0-18 years of age) after removal • This medicine is for the short term treatment of acute moderate pain Market/s: UK of their tonsils or adenoids due to obstructive sleep apnoea syndrome when other painkillers have not worked. • If you know that you metabolise very rapidly codeine into morphine • You should only take this product for a maximum of 3 days at a time. If Dimensions: 150 x 100mm (Drw No. L613D005) • If you are breastfeeding. you need to take it for longer than 3 days you should see your doctor or pharmacist for advice. Printer: Santiago Gonzalez • This medicine contains codeine which can cause addiction if you take it Ask your doctor before you take this medicine: continuously for more than 3 days. This can give you withdrawal Substrate: Paper symptoms from the medicine when you stop taking it. • If you have liver or kidney disease, including alcoholic liver disease Tablets EAN Code: N/A • If you take this medicine for headaches for more than 3 days it can make • If you have bowel problems including blockage of your bowel them worse.
    [Show full text]
  • Procedure Description Charge Amount 0302000014 ROOM MED
    Charge Procedure Description Amount 0302000014 ROOM MED SURG MOSU 1,040.00 0302000015 ROOM MED SURG PEDS 3,500.00 0302000033 OUT PATIENT BED MOSU 0.00 0302000035 ROOM INTERMEDIATE MOSU 2,055.00 0302000043 ROOM HOSPICE MOSU 805.00 0302000045 ROOM MED SURG W TELE MOSU 1,530.00 0302000050 OBSERVATION INTERM PER HR MOSU 97.00 0302002283 FECAL MANAGEMENT SYSTEM 694.00 0302010232 CATH INDWELL BLADDER SIMPLE 185.00 0302010304 OBSERVATION MS PER HR MOSU 60.00 0302010305 OBSERVATION TELE PER HR MOSU 71.00 0302010556 NONBILLABLE OBSERVATION HR 0.00 0302010557 OBSERVATION DIRECT ADM MOSU 130.00 0302020287 SUPPLIES CHEST TUBE 228.00 0302050318 LUMBAR PUNCTURE DIAGNOSTIC 1,035.00 0302050451 IV INF THERAPEUTIC EA ADD HR 170.00 0302050453 IV INF THERAPEUTIC UP TO 1HR 635.00 0302050454 IRRIGATION BLADDER 780.00 0302050480 INSERT VENOUS CENTRAL LINE 1,315.00 0302050490 IV PUSH INITIAL DRUG 380.00 0302050534 I&D ABSCESS SIMPLE 675.00 0302050603 IV PUSH EA SEQUENTIAL DRUG 153.00 0302050648 HEMODIALYSIS SERVICE IP 1,455.00 0302050813 ARTHROCENTESIS MAJ JNT WO IMAG 630.00 0302050885 ADMIN IMMUNIZATION 145.00 0302050948 DIALYSIS INTRAPERITONEAL SERV 655.00 0302060002 INJECTION SUB-Q/IM 155.00 0302060008 CHEMO ADMIN IV INF EA ADD HR 410.00 0302060101 HEMODIALYSIS SERVICE OBS/OP 1,455.00 0302060269 US PV RESIDUAL URINE 240.00 0302060274 IV PUSH EA ADD DRUG 168.00 0302060275 IV INF CONCURRENT THERAPEUTIC 385.00 0302060276 IV INF SEQUENTIAL THER UP TO 1 191.00 0302060293 INSERT STRAIGHT CATH THERAPEUT 185.00 0302060372 CHEMO ADMIN IV INF SEQ 1 HR 525.00 0302060373
    [Show full text]
  • Glaxosmithkline Plc Annual Report for the Year Ended 31St December 2000
    GlaxoSmithKline 01 GlaxoSmithKline plc Annual Report for the year ended 31st December 2000 Contents Report of the Directors 02 Financial summary 03 Joint statement by the Chairman and the Chief Executive Officer 05 Description of business 29 Corporate governance 37 Remuneration report 47 Operating and financial review and prospects 69 Financial statements 70 Directors’ statements of responsibility 71 Report by the auditors 72 Consolidated statement of profit and loss 72 Consolidated statement of total recognised gains and losses 74 Consolidated statement of cash flow 76 Consolidated balance sheet 76 Reconciliation of movements in equity shareholders’ funds 77 Company balance sheet 78 Notes to the financial statements 136 Group companies 142 Principal financial statements in US$ 144 Financial record 153 Investor information 154 Shareholder return 156 Taxation information for shareholders 157 Shareholder information 158 Share capital 160 Cross reference to Form 20-F 162 Glossary of terms The Annual Report was approved by the Board 163 Index of Directors on 22nd March 2001 and published on 12th April 2001. Contact details 02 GlaxoSmithKline Financial summary 2000 1999 Increase Business performance £m £m CER % £ % Sales 18,079 16,164 9 12 Trading profit 5,026 4,378 12 15 Profit before taxation 5,327 4,708 11 13 Earnings/Net income 3,697 3,222 13 15 Earnings per Ordinary Share 61.0p 52.7p 14 16 Total results Profit before taxation 6,029 4,236 Earnings/Net income 4,154 2,859 Earnings per Ordinary Share 68.5p 46.7p Business performance: results exclude merger items and restructuring costs; 1999 sales and trading profit exclude the Healthcare Services businesses which were disposed of in 1999.
    [Show full text]
  • TITLE Safety and Efficacy of Over-The-Counter Drug Use by the Elderly
    " DOCUMENT RESUME ED 245 148 CG 017 518 TITLE Safety and Efficacy of Over-the-Counter Drug Use by the Elderly. Hearing before the Subcommittee on Health and Long-Term Care of the Select Committee on Aging. House of Representatives, Ninety-Eighth Congress, First Session. INSTITUTION Congress of the U.S., Washington, D.C. House Select Committee on Aging. REPORT NO House-Comm-Pub-98-409 PUB DATE 21 Jul 83 NOTE 507p.; Some pages are marginally legible due to small print. PUB TYPE Legal/Legislative/Regulatory Materials (090) EDRS PRICE MF02 Plus Postage. PC Not Available from EDRS. DESCRIPTORS *Consumer Protection; Dietetics; Drug Legislation; *Drug Use; Gerontology; Hearings; *Older Adults; Physical Health; *Safety IDENTIFIERS Congress 98th; Long Term Care; *Nonprescription Drugs; *PPA ABSTRACT This document contains the prepared statements and panel testimony from the Congressional hearing on over-the-counter (OTC) drug use by the elderly. Opening statements are given by Representatives Claude Pepper (chairman), Ralph Regula, Mary Rose Oakar, Michael Bilirakis, Tom Lantos, and Hal Daub. Topics which are covered include the incidence and quantity of drug use by the elderly, health risks, adverse reactions, phenylpropanolamine (PPA), consumer protection, and the Federal Drug Administration's (FDA) role in the OTC drug safety and reguIatiem. Testimony of the first panel on OTC drugs, particularly weight reduction medications containing PPA, is given by representatives of the Health Research Group, the National Broadcasting Company, and consumers. Testimony of the second panel on mail fraud schemes perpetrated against senior citizens is given by consumer advocates representing the United States Postal Service, Criminal Investigations and Consumer Protection Divisions, and the Center for Science in the Public Interest.
    [Show full text]
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]